Clinical Trial

Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

Study acronym: TREAZURE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open-label, prospective, phase 2 study of trastuzumab, bevacizumab, and paclitaxel as second-line treatment for patients with HER2-positive advanced gastric cancer who had progressed on first-line chemotherapy including trastuzumab or anti-HER2 agents.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-12-05; most recent amendment 2024-11-23.
Status change: Not Yet Recruiting → Recruiting 2023-03-07
Trial Details
NCT Number NCT05640830
Lead Sponsor Kangbuk Samsung Hospital
Conditions HER2-positive Advanced Gastric Cancer
Enrollment 47 participants
Start Date 2023-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-26